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An 84-year-old black male from Botswana presented to our
Oncology Clinic with a 15-year history of dark brown nodules
and peripheral edema located mostly on his lower limbs with
gradual extension. Biopsy conﬁrmed Kaposi sarcoma (KS,
Figure1) and human herpes virus 8 stain was positive. Human im-
munodeﬁciency virus (HIV) antibody was negative. The patient
underwent combination chemotherapywith doxorubicin, bleomy-
cin, and vincristine as ﬁrst line, and monotherapy intravenous eto-
poside as second line, without response. This was followed by
three sessions of external beam radiotherapy with x-ray beam to
the lower extremities (ﬁrst session was 24 Gy/12 fractions to bilat-
eral the lower legs, second and third sessions were 12 Gy/6 frac-
tions to the left lower leg, respectively). In October 2013, the
patient presented to our clinic with ulcerations and nodules on
his left foot (Figure 2A) and bilateral swelling of the hands, fore-
arms, and legs. His Eastern cooperative oncology group perfor-
mance status (ECOG PS) was 2. Chest, abdominal, and pelvic
computed tomography showed no signiﬁcant abnormality. Doce-
taxel monotherapy was administered intravenously at a dose of
30 mg/m2 weekly. There were no signiﬁcant adverse events re-
ported. After six doses, the KS lesions and edema had completely
disappeared (Figure 2B), leaving behind a small scar on the sole
of the left foot. ECOG PS was 0 upon cessation of chemotherapy.
During a 12-month follow-up period, the patient did not develop
any new KS lesions and ECOG PS remained at 0.Figure 1 (A) Proliferation of small, irregular vascular vessels with extravasated red blood
packed proliferation of irregular small vascular vessels lined by a single layer of mildly atypi
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properties in vitro and in vivo.1 Stoebner et al2 reported a dissemi-
nated classic KS case given docetaxel (60 mg/m2 3-weekly), which
showed an almost complete disappearance of all skin lesions after
three infusions. Fardet et al3 reported on nine nonHIV-infected re-
fractory KS cases including seven classic KS cases treated with the
same docetaxel dose. Median number of cycles of chemotherapy
was six (range, 2e8). All cases had a partial response. However,
three patients experienced Grade 3 or 4 neutropenia.
Classic KS predominantly affects elderly people over 50 years,
many of whom do not tolerate aggressive chemotherapy regimens
well due to frequent comorbidity and diminished cardiovascular
and bone marrow reserves. Classic KS follows an indolent course
(average survival is 10e15 years) requiring long-term and repeated
chemotherapy.4 Therefore, lowering the toxicity of docetaxel
without compromising the efﬁcacy for elderly patients was
investigated.
Phase 2 and 3 studies have demonstrated that weekly docetaxel
in metastatic breast carcinoma had less toxicity including neutro-
penia or febrile neutropenia, in comparison with 3-weekly doce-
taxel.5,6 Lim et al7 used docetaxel at 25 mg/m2 in advanced-stage
AIDS-associated KS and reported 42% partial response rate with
33% Grade 3 neutropenia and no Grade 4 toxicity. By contrast to
classic KS, AIDS associated KS patients are immunocompromised.
In light of this, we speculated that weekly docetaxel in classic KS
could potentially offer a better outcome with fewer side effects
than in AIDS-associated KS.cells and inﬂammatory inﬁltrate [Hematoxylin and eosin (H & E)  200]; (B) closely
cal endothelial cells. Extravasated red blood cells surround these vessels (H & E  400).
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Figure 2 (A) Multiple brown-dark ulcerations and nodules localized on the left foot; (B) Kaposi sarcoma lesions completely disappeared in the same area of the left foot with only a
small scar left after six doses of docetaxel (30 mg/m2 weekly).
Correspondence / Dermatologica Sinica 34 (2016) 108e109 109In our case report, weekly docetaxel 30 mg/m2 in an elderly pa-
tient with refractory classic KS offered a complete response as well
as improvement of performance status. To our knowledge, this is
the ﬁrst case report to address the use of weekly docetaxel
(30 mg/m2) in classic KS.
Another question raised from our case report is “how many
doses of docetaxel are appropriate in classic KS to obtain
maximum effect with minimum toxicity?” A study by Vacca
et al1 showed very low docetaxel and paclitaxel doses selectively
causes organic and functional damage of endothelial cells of KS
and that docetaxel is four times stronger. In our case, only six
doses of weekly docetaxel (total dose was 180 mg/m2) gave the
patient durable remission. The total dose of 180 mg/m2 was
consistent with another case detailing a complete response for
every 3 week dosing for classic KS by Stoebner et al2 and a case
by Fardet3 which generated a 20-month remission of classic KS le-
sions. The total number of doses for docetaxel to achieve the most
effective response in this setting is not well understood, however
limited pilot data suggests a low dose of docetaxel may produce
good effects with low toxicity. Neurotoxicity in particular appears
to be dose dependent, which will impact repeated delivery of
docetaxel.8
A reduced dose of weekly docetaxel could provide good efﬁcacy
with reduced toxicity, which is a fair ﬁt for elderly patients or those
with a proﬁle of indolent course. Further investigations are
required to support our hypothesis of the efﬁcacy and toxicity of
weekly docetaxel in classical KS, particularly in older populations,
as well as to ﬁgure out how many doses of weekly docetaxel is
appropriate to maximize the efﬁcacy and minimize the toxicity.
Rongbo Lin*
Department of Oncology, Princess Marina Hospital, Gaborone, Botswana
Department of Gastrointestinal Medical Oncology, Fujian Provincial Cancer Hospital,
Fujian Medical University Teaching Hospital, Fuzhou, PR ChinaFujian Key Laboratory of Translational Cancer Medicine, Fuzhou, PR China
Ryan Hodgeman
Botswana Harvard Partnership, Princess Marina Hospital, Gaborone, Botswana
Feng Zhou
National Health Laboratory of Botswana, Gaborone, Botswana
* Corresponding author. Department of Oncology, Princess Marina Hospital, P.O.
BOX 258, Gaborone, Botswana.
E-mail address: linrongbo@medmail.com.cn (R. Lin).References
1. Vacca A, Ribatti D, Iurlaro M, et al. Docetaxel versus paclitaxel for antiangiogen-
esis. J Hematother Stem Cell Res 2002;11:103e18.
2. Stoebner PE, Nocera T, Meynadier J, Meunier L. Efﬁcacy of docetaxel in dissem-
inated classical Kaposi's sarcoma. Br J Dermatol 2000;143:1357e9.
3. Fardet L, Stoebner PE, Bachelez H, et al. Treatment with taxanes of refractory or
life-threatening Kaposi sarcoma not associated with human immunodeﬁciency
virus infection. Cancer 2006;106:1785e9.
4. Akasbi Y, Awada A, Ariﬁ S, Mellas N, El Mesbahi O. NonHIV Kaposi's sarcoma: a
review and therapeutic perspectives. Bull Cancer 2012;99:92e9.
5. Tabernero J, Climent MA, Lluch A, et al. A multicentre, randomised phase II study
of weekly or 3-weekly docetaxel in patients with metastatic breast cancer. Ann
Oncol 2004;15:1358e65.
6. Rivera E, Mejia JA, Arun BK, et al. Phase 3 study comparing the use of docetaxel
on an every-3-week versus weekly schedule in the treatment of metastatic
breast cancer. Cancer 2008;112:1455e61.
7. Lim ST, Tupule A, Espina BM, Levine AM. Weekly docetaxel is safe and effective in
the treatment of advanced-stage acquired immunodeﬁciency syndrome-related
Kaposi sarcoma. Cancer 2005;103:417e21.
8. Hilkens PH, Verweij J, Stoter G, Vecht CJ, van Putten WL, van den Bent MJ. Pe-
ripheral neurotoxicity induced by docetaxel. Neurology 1996;46:104e8.Received: Apr 11, 2015
Revised: Sep 9, 2015
Accepted: Sep 21, 2015
